Article
Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India.
Indian journal of cancer - 1 Mar 2022
Malik Prabhat S, Noronha Vanita, Dabkara Deepak, Maddu Vamshi K, Rajappa Senthil, Limaye Sewanti, Batra Ullas
Abstract excerpt
Background: A Phase IV, single-arm study was conducted to assess the safety of osimertinib in Indian patients with epidermal growth factor receptor (EGFR) T790M mutation-positive stage IV non-small cell lung cancer (NSCLC). Methods: Enrolled patients received 80 mg osimertinib for six cycles or until disease progression or unacceptable toxicity or withdrawal. Primary safety variables included treatment-emergent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.